The spike in ZyVersa Therapeutics' stock price can be attributed to positive investor sentiment following the circulation of promising information about its NLRP3 drug IC 100. This drug, being investigated for treating damaging inflammation associated with serious conditions such as obesity-related heart disease, represents a significant potential market and a breakthrough in treatment options. The news likely increased investor confidence in the company's research and development capabilities and its potential for future revenue growth.